Neuromedin U-25: gut and brain signaling peptide (porcine form)

What this is

Neuromedin U-25 (porcine) is a 25-amino-acid signaling peptide first isolated from pig spinal cord in 1985 by Minamino and colleagues, who named it for its striking ability to contract rat uterine smooth muscle. It belongs to the neuromedin U (NMU) family — a group of neuropeptides found across vertebrates in the gut, spinal cord, and brain that regulate smooth muscle tone, appetite, and stress responses. The porcine 25-residue form (NMU-25) is the longest isoform identified in pig and shares with all vertebrate NMUs a highly conserved amidated C-terminal pentapeptide (-Phe-Arg-Pro-Arg-Asn-NH₂) that is the pharmacologically active core; this C-terminal amide is absent from the raw sequence stored here but is essential for receptor activation (Brighton and colleagues, Pharmacological Reviews, 2004).

History

Neuromedin U was discovered in 1985 when Minamino and colleagues purified two novel smooth-muscle-stimulating peptides — NMU-8 and NMU-25 — from porcine spinal cord extracts and reported their uterotonic and hypertensive activities. The naming convention "U" directly reflects this founding bioassay: contraction of rat uterus tissue. For the following fifteen years, NMU was studied as a smooth-muscle peptide of uncertain physiological significance. The field accelerated sharply in 2000, when several research groups simultaneously deorphanized the G-protein-coupled receptors that NMU activates: Howard and colleagues, Fujii and colleagues, Hedrick and colleagues, and Raddatz and colleagues each independently identified NMUR1 (previously orphan receptor FM-3/GPR66) and NMUR2 (FM-4) as the cognate NMU receptors, enabling systematic study of its central and peripheral roles. A closely related peptide, neuromedin S (NMS), was identified in 2005 by Mori and colleagues as a second endogenous ligand at both receptors.

What it does

Neuromedin U-25 (porcine) acts on two G-protein-coupled receptors — NMUR1, found predominantly in peripheral tissues such as the gut and adrenal cortex, and NMUR2, found predominantly in specific brain regions — producing distinct effects depending on where it acts. In the periphery, NMU contracts smooth muscle in the uterus, intestine, and urinary bladder, raises blood pressure, modifies ion transport in the gut, and regulates adrenal function. In the brain, centrally administered NMU strongly suppresses food intake, increases energy expenditure, raises core body temperature, and activates the hypothalamic-pituitary-adrenal (HPA) stress axis by stimulating corticotropin-releasing hormone (CRH) release. Genetic studies confirm its metabolic role: mice lacking NMU develop obesity, late-onset hyperlipidemia, and fatty liver; mice engineered to overexpress NMU remain lean even when fed a high-fat diet (Brighton and colleagues, 2004; review in Frontiers in Endocrinology, 2021).

Evidence

• Human: No clinical trials have been conducted with neuromedin U-25 (porcine) as a therapeutic agent. Human genetic studies have identified NMU gene polymorphisms associated with obesity phenotypes in Caucasian populations and childhood-onset obesity with hypertriglyceridemia, consistent with the preclinical energy-homeostasis role (reviewed in PMC8074168, 2021). No registered trials appear on ClinicalTrials.gov for neuromedin U-25.
• Animal: Extensive preclinical evidence in rodents. Chronic central infusion of NMU decreased food intake and body weight in both lean and obese mice, and increased core body temperature; these effects were abolished in NMUR2-knockout animals, establishing NMUR2 as the central mediator of the anorexigenic response (review: Frontiers in Endocrinology, 2021). Species-dependent smooth-muscle contraction to NMU has been characterized across multiple tissues (mouse forestomach, chicken crop, rat uterus), with receptor subtype contributions examined using NMUR1-knockout mice (PubMed PMID 16474416).
• In vitro: Receptor activation triggers intracellular Ca²⁺ elevation and phospholipase C activation. NMUR1 couples predominantly via Gαq/11; NMUR2 via Gαi pathways. ILC2 stimulation with NMU in combination with IL-25 enhanced rapid secretion of type 2 cytokines (IL-5, IL-9, IL-13) in a cell-intrinsic NMUR1-dependent manner (Cardoso and colleagues, 2017, cited in review PMC7730025).

Known effects

• Uterine smooth muscle contraction — Founding pharmacological activity; preclinical (the defining bioassay from original 1985 isolation)
• Blood pressure elevation — Preclinical; both central and peripheral administration
• Gut motility modulation — Preclinical; prokinetic effect on colon via enteric nerve-mediated NMUR1 activation
• Appetite suppression / anorexigenic — Preclinical rodent models; NMUR2-dependent central effect
• Energy expenditure increase — Preclinical; increased physical activity, thermogenesis, reduced adiposity
• HPA axis activation — Preclinical; CRH → ACTH → cortisol/corticosterone cascade
• ILC2 and type 2 immune activation — Preclinical; NMUR1-mediated activation of innate lymphoid cells and mast cell degranulation

Safety signals

No human safety data exist for neuromedin U-25 (porcine) as an administered compound. In preclinical settings, the hypertensive and uterotonic activities documented since 1985 are the primary acute pharmacological signals — relevant context for any experimental use. Immune effects (ILC2 activation, mast cell degranulation) represent additional biology to monitor in animal models, given NMU's documented role in amplifying type 2 allergic inflammation in OVA-induced asthma models (reviewed in Moriyama and colleagues, 2006, cited in PMC7730025).

Mechanism

NMU-25 is an agonist at both NMUR1 and NMUR2, two class A GPCRs with seven transmembrane domains. Receptor binding triggers Gαq/11-mediated phospholipase C activation and intracellular Ca²⁺ mobilization (primarily NMUR1) and Gαi signaling (predominantly NMUR2). The biological selectivity between the two receptor subtypes reflects their differential expression — not differential affinity, as NMU binds both with comparable potency. The amidated C-terminal pentapeptide (-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH₂) is the conserved pharmacophore across vertebrate NMU forms; full-length NMU-25 presents this active core together with the N-terminal extension that influences species-specific tissue distribution and receptor engagement kinetics. Within the hypothalamus, the anorexigenic signal is relayed downstream through melanocortin and CRH pathways, with sympathetic outflow driving the thermogenic component (Brighton and colleagues, Pharmacological Reviews, 2004).

Open questions

• No selective NMUR1 vs. NMUR2 agonist or antagonist has advanced to human trials; whether central (NMUR2-targeted) anti-obesity pharmacology is feasible in humans remains untested
• The cancer biology of NMU — overexpression in colorectal, breast, and endometrial tumors with autocrine signaling through NMUR1 — raises the question of whether NMU receptor antagonism could have anti-tumor utility
• Half-life of native NMU-25 in circulation has not been well characterized; analogs with protease-resistance modifications are under active investigation
• The relationship between the porcine NMU-25 sequence stored here and the human NMU-25 sequence (FRVDEEFQSPFASQSRGYFLFRPRN-NH₂) reflects species differences outside the conserved C-terminal core — the biological significance of the N-terminal divergence between species is not fully resolved

Related peptides

• Neuromedin S (NMS) — the structurally related neuropeptide identified in 2005 that shares NMUR1 and NMUR2 as its receptors; has overlapping but not identical expression pattern and biological roles
• Neuromedin U-8 (porcine) — the shorter isoform co-purified with NMU-25 in the original 1985 isolation; contains the active C-terminal octapeptide and shows comparable contractile potency in many assays